True Freedom Investing LLC Buys New Holdings in Abbott Laboratories $ABT

True Freedom Investing LLC purchased a new stake in shares of Abbott Laboratories (NYSE:ABT - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 43,409 shares of the healthcare product maker's stock, valued at approximately $4,457,000.

Other large investors also recently modified their holdings of the company. Cornerstone Financial Management LLC acquired a new stake in Abbott Laboratories during the 4th quarter worth approximately $25,000. MidAtlantic Capital Management Inc. purchased a new stake in Abbott Laboratories during the fourth quarter worth approximately $25,000. Purpose Unlimited Inc. acquired a new stake in shares of Abbott Laboratories in the fourth quarter worth $25,000. Portfolio Resources Advisor Group Inc. acquired a new stake in shares of Abbott Laboratories in the fourth quarter worth $26,000. Finally, Abound Financial LLC purchased a new position in shares of Abbott Laboratories in the 4th quarter valued at $26,000. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Abbott Laboratories Stock Down 1.8%

Shares of Abbott Laboratories stock opened at $110.48 on Tuesday. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $137.49. The company has a market capitalization of $191.17 billion, a PE ratio of 35.75, a P/E/G ratio of 2.18 and a beta of 0.59. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. The business has a 50-day moving average of $103.06 and a 200-day moving average of $100.13.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, beating analysts' consensus estimates of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The firm had revenue of $12.59 billion during the quarter, compared to the consensus estimate of $12.52 billion. During the same quarter in the prior year, the business posted $1.26 earnings per share. Abbott Laboratories's revenue for the quarter was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, equities analysts forecast that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th were given a dividend of $0.63 per share. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. Abbott Laboratories's dividend payout ratio (DPR) is presently 81.55%.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on ABT. Royal Bank Of Canada reiterated an "outperform" rating and issued a $130.00 price target on shares of Abbott Laboratories in a report on Friday, July 17th. Wolfe Research raised Abbott Laboratories from a "peer perform" rating to an "outperform" rating and set a $130.00 target price for the company in a research report on Thursday, August 13th. JPMorgan Chase & Co. increased their target price on Abbott Laboratories from $110.00 to $120.00 and gave the company an "overweight" rating in a research note on Friday, July 17th. Piper Sandler reissued an "overweight" rating and set a $118.00 price target (up from $115.00) on shares of Abbott Laboratories in a research report on Friday, July 17th. Finally, TD Cowen increased their price objective on shares of Abbott Laboratories from $115.00 to $135.00 and gave the company a "buy" rating in a research report on Tuesday, August 25th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $119.50.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source